Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
RedHill will host an Analyst and Investor Webcast on TALICIA ® for H. pylori infection on Tuesday, October 30, 2018 , at 8:30 a.m. EDT Final patient assessed for primary endpoint, with top-line results expected before year-end 2018   If successful, RedHill plans to file a U.S. ...
View HTML
Toggle Summary RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018
The presentation highlighted enhanced p-values for previously reported outcomes, including the primary endpoint of clinical remission at week 26 (p=0.007) and key secondary and other efficacy endpoints of clinical response at week 26 (p=0.016), early clinical remission at week 16 (p=0.015), ...
View HTML
Toggle Summary RedHill Biopharma Late-Breaking Abstract on Positive Phase III Crohn’s Disease Study with RHB-104 to be Presented at UEG Week 2018
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA ® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders In light of the clarity provided by the FDA regarding the clinical and regulatory pathway for ...
View HTML
Toggle Summary RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
The first stage of the Phase IIa study with YELIVA ® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its second stage, enrolling the full cohort of 39 evaluable patients who previous ...
View HTML
Toggle Summary RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection
Top-line results from the randomized, double-blind confirmatory Phase III study (ERADICATE Hp2 study) with TALICIA ® are expected before year’s end     The ERADICATE Hp2 study enrolled 455 patients with confirmed H. pylori infection in 55 clinical sites across the U.S. ...
View HTML
Toggle Summary RedHill Biopharma Reports Second Quarter 2018 Financial Results and Provides Update on Operations
Key Highlights: Top-line results from confirmatory Phase III study with TALICIA ® for H. pylori infection on track to be announced in the fourth quarter of 2018   Positive top-line results from Phase III study with RHB-104 for Crohn’s disease - the study successfully met both its primary endpoint ...
View HTML
Toggle Summary RedHill Biopharma to Host Second Quarter 2018 Financial Results Conference Call on August 30, 2018
TEL-AVIV, Israel and RALEIGH, N.C. , Aug. 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation
Once granted, the new formulation patent is expected to be valid until at least 2033 RHB-106 is an encapsulated bowel preparation with worldwide rights licensed to Salix Pharmaceuticals   RedHill and Salix recently amended their license agreement to include certain development activities, timelines ...
View HTML